About Herapin Therapeutics
Welcome to Heparin Therapeutics, where cutting-edge medical research meets unparalleled dedication to improving patient outcomes. As pioneers in the field of heparin and inhalation-administered drugs, we are committed to advancing healthcare through innovation, integrity, and excellence.
Our team of world-class scientists and researchers specialize in the development and optimization of heparin-based therapies, pushing the boundaries of medical science to offer groundbreaking solutions for a range of medical conditions. With a focus on inhalation administration, we aim to develop safe and highly differentiated pulmonary treatments for acute and chronic respiratory diseases to that enhance patient comfort and compliance.
There is a significant unmet need for treatments aimed at reducing lung inflammation in both ICU and outpatient settings. Prolonged time on ventilators is associated with poor outcomes, underscoring the necessity for effective therapies.
The efficacy and safety of Unfractionated Heparin in the treatment of respiratory disease has been demonstrated through more than 50 clinical studies involving our founders investigating the off-label nebulisation of commercially available of heparin injections in respiratory disease. However, despite the impressive clinical outcomes such an approach results in sub-optimal suboptimal lung delivery and retention and is impractical for routine clinical use and so currently, no approved inhaled UFH product exists.
Heparin Therapeutics is pioneering HT-231, the first patented, safe, and well- tolerated unfractionated heparin (UFH) nebulized medicine utilizing our proprietary drug delivery platform, for the treatment of Acute Respiratory Distress Syndrome (ARDS). This PoC data is expected to be translatable to other prevalent lung diseases including Chronic Obstructive Pulmonary disease (COPD), Asthma, Idiopathic Pulmonary Fibrosis (IPF) and Bronchiectasis.
Founders
-
Professor Frank Van Haren MD PhD EDIC FCICM PGDipEcho
Frank van Haren is Professor at the Australian National University’s College of Health and Medicine and Director of the Intensive Care Unit at St George's Hospital in Sydney, Australia. He is also Conjoint Professor at the University of New South Wales, Adjunct Professor at the University of Canberra, and honorary Professorial Fellow at the George Institute for Global Health. He is an established international leader and expert in clinical and translational research. He has led 2 investigator-initiated multi-national collaborative COVID-19 studies investigating inhaled heparin. He has published over 160 articles and book chapters and given over 140 invited presentations at international scientific conferences.
-
Prof. Clive Page OBE, BSc, PhD, FSoB, FBPhS
Clive Page is a member of the Scientific Advisory Committee at MedPharm and Professor of Pharmacology at King’s College London. He is Co-Founder and previous Chairman of the Board of Verona Pharma plc, a NASDAQ listed company developing new drugs for the treatment of respiratory diseases and has held Non-Executive Board positions at Stirling Products Ltd, Revolo (formerly Immune Regulation Ltd) and Babraham Biotechnology Ltd. Professor Page was awarded an OBE for “Services to Pharmacology” in 2017 and has recently served as a Non-Executive Director of PreP Biopharma and as Non-Executive Chairman of the Board of EpiEndo. Clive is also Trustee of the Fraunhofer Institute of Experimental Medicine and Toxicology in Hannover and the William Harvey Research Foundation in the UK.
-
Prof. Marc Brown BSc PhD CChem FRSC
Marc Brown co-founded MedPharm in August 1999. He has been the guiding force behind all of MedPharm’s scientific developments and intellectual property. He has been Professor of Pharmaceutics and Toxicology in the School of Pharmacy, University of Hertfordshire since 2006 and has visiting/honorary professorships at the Universities of Reading and King’s College London. He has over 200 publications and 26 patents describing his work. His research interests lie mainly in drug delivery to the skin, nail and airways. To date, he has been involved in the pharmaceutical development of over 55 products that are now on the market in Europe, America and Japan. He is a scientific advisor in formulation development for numerous pharma companies around the world.
Advisors
-
Norman Barras
Chairman
Norman Barras has an BSc. in Chemistry from the University of the West of Scotland and an MSc. in Biochemical Pharmacology from the University of Hertfordshire.
Mr. Barras has over forty years of experience in the Pharmaceutical Industry, working at, Vice President/Director level in; Pharmaceutical Research; Product Development; Manufacturing; International Registration and Business Development of drug products. He has held Senior positions at: Patheon, Vice President Global Clinical Manufacturing (USA, Canada, Europe and Asia Pacific); Lonza Biologics, Managing Director (Slough); Norgine B.V. Vice President Pharmaceutical Research (USA and Europe) and Managing Director PCI Pharma Services (formerly Penn Pharma).
With extensive knowledge of taking drugs from concept all the way to market and with expertise in dealing with Global Regulatory Agencies such as the FDA, MHRA, EMA among others.
A member of the Scientific Advisory Committee at MedPharm as well as holding a number of Board positions with both Pharmaceutical Research, Manufacturing and Pharmaceutical Packaging Companies.
-
Sarah Vale BMeDSc, BN
Advisor
She is co-founder and major shareholder of an Australian private entity, Mucpharm Pty Ltd, developing targeted therapeutics in oncology, infection and respiratory conditions.
Through establishing and growing the company, Sarah now holds Chief Operating Officer responsibilities and coordinates the scientific and clinical development programs, managing 14 senior scientists. She is familiar with private and publicly listed requirements of business in Australia and business development in the USA.
Sarah has more than 10 years preclinical research and clinical trial experience in both new drug, biologics and device developments. She manages regulatory US FDA and EMA submissions (orphans, INDs, protocol advice, scientific assistance Sarah is an inventor on several patents including new drug and device patents. She has coordinated capital raise of more than USD $65 million over a three year period and two out-licensing (upfront, milestone and royalty) deals surrounding distribution and sales rights.
-
Dr Jonathan Talbott MA PhD
Advisor
Dr. Talbot has a Bachelor of Science in Biochemistry and Pharmacology and a PhD in Pharmacy from The University of London, King’s College, and a Masters in Finance from ESCP-EAP in Paris. After completing his education in Pharmaceutical Sciences and Finance, Jonathan started his career at a Biotech Startup in Paris as a Business Analyst at Deinove SA. He then went onto work in Life Science Consulting before building a successful 12-year career in the Pharmaceutical Industry. Dr. Talbot has broad industry experience with a strong track record in Pharma. Initially as a Forecast Manager for the Neurodegenerative Diseases Franchise at Merck Serono before moving to Roche. Most recently, he served as Global Scientific Director at Roche, supporting product development from early stage through to the launch of several innovative programs including programs in the antibody-drug-conjugate and immuno-oncology space. Prior to that, Dr. Talbot led a team in Roche Partnering. He supported the completion of several Global drug licensing deals and strategic corporate acquisitions most notably, a one billion dollar investment in Foundation Medicine.
Partners
